Glycated hemoglobin

Sugar can stick to your red blood cells.

These cells live for a few months. When sugar is in your blood, it joins the cells. This happens on its own. The more sugar you have, the more it sticks.

Doctors use a test to see this. The test shows your sugar levels over time. It helps them see if you are healthy. It is a smart way to check your body. This helps keep you well.

Sugar can stick to your red blood cells.

This happens through a way called glycation. In glycation, sugar joins with hemoglobin. Hemoglobin is a part of your red blood cells. This happens on its own without help from the body.

When you have a lot of sugar in your blood, more of it sticks. This is a sign of diabetes. Doctors use a test called A1c to measure this. The A1c test shows your average blood sugar levels. It looks at the last two or three months. We know this because red blood cells live for about three to four months. Once sugar sticks to a cell, it stays there.

High sugar levels can cause many problems. They can hurt your heart and your eyes. They can also hurt your kidneys and your nerves. Too much sugar makes blood cells clump together. This can make it hard for blood to flow. Doctors use the A1c test to help keep people healthy. It helps them see if a person's sugar is under control.

Glycated hemoglobin is a special type of hemoglobin that has sugar stuck to it. Hemoglobin is a part of your red blood cells that helps carry oxygen. When sugars like glucose, galactose, or fructose are in your blood, they can bond with hemoglobin. This bonding happens on its own without help from the body's enzymes. This natural process is called glycation.

Because glucose is the main fuel for humans, it is the most important sugar to watch. If there is too much sugar in the blood, more of it will stick to the hemoglobin. This can be a sign of diabetes or other hormone diseases.

How does this process work step by step? First, a sugar molecule like glucose meets the hemoglobin in a red blood cell. The sugar then attaches to the end of a part of the hemoglobin called the beta chain. This creates something called a Schiff base. Next, the molecule goes through a change called an Amadori rearrangement. This change turns the molecule into something called 1-deoxyfructose. Once this sugar is stuck to the hemoglobin, it stays that way for the rest of the cell's life.

This makes it a great way to see how much sugar has been in the blood over time.

Scientists have studied this for many years to help people with diabetes. In 1958, Huisman and Meyering first separated this type of hemoglobin using a tool called a chromatographic column. Later, in 1968, Bookchin and Gallop identified it as a glycoprotein. In 1969, Samuel Rahbar and his coworkers discovered that its levels go up in people with diabetes. By 1975, Bunn and his team explained the chemical reactions that cause it to form. Finally, in 1976, Anthony Cerami and Ronald Koenig suggested using it to monitor glucose in patients.

Doctors use a specific test called HbA1c to measure these levels. This test is very useful because it shows a three-month average of blood sugar. We know this because red blood cells live for about three to four months. For men, the average life is 117 days, and for women, it is 106 days. The test can be done in many ways, such as using high-performance liquid chromatography. Some quick tests can even be used right in a doctor's office.

These measurements help doctors see if a person's treatment is working well.

It is important to keep sugar levels in a healthy range. If glycated hemoglobin levels stay too high, it can cause many problems. It can lead to heart disease, kidney problems, and nerve damage. It can even affect your eyes or cause blindness. High sugar can also make blood cells clump together, which makes the blood thicker. This can make it harder for blood to flow through your vessels. By using the A1c test, doctors can help prevent these serious issues.

Glycated hemoglobin is a specific form of hemoglobin that has chemically bonded with a sugar molecule. Hemoglobin is the protein inside red blood cells that carries oxygen throughout the body. When various monosaccharides, such as glucose, galactose, or fructose, are present in the bloodstream, they spontaneously bond with this protein. This bonding process is called glycation, and it occurs without the help of enzymes. While several sugars can trigger this, glucose is the most significant because it serves as the primary metabolic fuel for humans. Measuring these sugar-hemoglobin linkages is vital because high levels often indicate diabetes or other hormone-related diseases.

The chemical mechanism of glycation follows a precise sequence of steps. First, a nonenzymatic condensation reaction occurs between a glucose molecule and the N-end of the hemoglobin's beta chain. This initial reaction produces a temporary structure known as a Schiff base. Following this, the molecule undergoes a second conversion called an Amadori rearrangement. This rearrangement transforms the Schiff base into 1-deoxyfructose. Once this process is complete, the sugar remains permanently attached to the hemoglobin molecule. Because the sugar stays stuck, the amount of glycated hemoglobin reflects the average glucose exposure over the entire life of that red blood cell.

Scientists use the term HbA1c to refer to a specific component of glycated hemoglobin, known as beta-N-1-deoxy fructosyl hemoglobin. The naming of HbA1c comes from how different types of hemoglobin A are separated using cation exchange chromatography. In this process, the first fraction to separate is called HbA0, which is pure hemoglobin A. The subsequent fractions are labeled HbA1a, HbA1b, and HbA1c based on their order of elution. While researchers have since found even more subfractions using improved separation techniques, HbA1c remains the standard for clinical testing.

The history of understanding HbA1c involves several decades of scientific discovery. In 1958, Huisman and Meyering first separated this form of hemoglobin using a chromatographic column. Later, in 1968, Bookchin and Gallop characterized it as a glycoprotein. A major breakthrough occurred in 1969 when Samuel Rahbar and his coworkers described how its levels increase in patients with diabetes. The specific chemical reactions were not fully understood until Bunn and his team characterized them in 1975. Finally, in 1976, Anthony Cerami and Ronald Koenig proposed using HbA1c to monitor glucose metabolism in diabetic patients.

Clinicians rely on the HbA1c test to determine a patient's three-month average blood sugar level. This timeframe is used because the average lifespan of a red blood cell is approximately three to four months. Specifically, the average lifespan is 117 days for men and 106 days for women. Because of this, glucose levels from the most recent days contribute more heavily to the final A1c result than older levels. Laboratories can measure these levels using various methods, including high-performance liquid chromatography, immunoassay, or capillary electrophoresis. Some point-of-care devices used in doctor's offices utilize immunoassay or boronate affinity chromatography.

High levels of glycated hemoglobin can lead to significant biological damage. This process increases highly reactive free radicals inside the blood cells, which alters their cell membranes. This can cause blood cells to aggregate, increasing blood viscosity and impairing blood flow. Furthermore, glycation can trigger inflammation and the formation of atherosclerotic plaques in the arteries. Highly glycated hemoglobin can also interfere with nitric oxide, a potent vasodilator that helps blood vessels relax. This degradation can lead to serious long-term complications, including cardiovascular disease, nephropathy, neuropathy, and retinopathy.

Managing HbA1c levels is a delicate balance for medical professionals. For most diabetic patients, the American Diabetes Association recommends maintaining levels below 7.0% DCCT. However, targets may change based on the individual's specific health needs. For example, more stringent targets below 6.0% might be preferred for pregnant patients. Conversely, intensive therapy to reach very low levels can sometimes increase the risk of dangerous hypoglycemic episodes. For those with conditions like sickle-cell disease or glucose-6-phosphate dehydrogenase deficiency, red blood cells may die prematurely. In these specific cases, doctors might use different tests, such as fructosamine, to assess glucose control over a shorter 2-to-3-week period.